Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26046466 | 0.86 | PRKCI (0.51) | HMGCRPRKCIALOX5GABRA1GABRB2 | |
| SCHEMBL17916383 | 0.85 | HMGCR (0.46) | HMGCRPRKCIALOX5GABRA1GABRB2 | |
| SCHEMBL12504376 | 0.83 | TRPV1 (0.43) | GABRA1GABRB2TRPV1POLB | |
| SCHEMBL2820470 | 0.83 | HMGCR (0.44) | HMGCRPRKCIALOX5GABRA1GABRB2 | |
| SCHEMBL31540301 | 0.83 | HMGCR (0.44) | HMGCRPRKCIALOX5GABRA1GABRB2 | |
| SCHEMBL6645942 | 0.83 | TRPV1 (0.55) | HMGCRPRKCIALOX5GABRA1GABRB2 | |
| SCHEMBL796853 | 0.82 | HMGCR (0.47) | HMGCRALOX5ELANE | |
| SCHEMBL26046493 | 0.82 | HMGCR (0.43) | HMGCRPRKCIALOX5GABRA1GABRB2 | |
| SCHEMBL25297854 | 0.81 | TNKS2 (0.39) | TRPV1AOC3POLBTYR | |
| SCHEMBL21317655 | 0.79 | POLB (0.61) | TRPV1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250290009-A1 | NEW LOW SULFUR TERPENE MIX RECOVERY FROM WOOD PROCESSING | FIRMENICH SA (CH) | 2025-09-18 | — | — | US | claimed |
| EP-4522714-A1 | NEW LOW SULFUR TERPENE MIX RECOVERY FROM WOOD PROCESSING | Firmenich SA (CH) | 2025-03-19 | — | — | EP | claimed |
| WO-2023217712-A1 | NEW LOW SULFUR TERPENE MIX RECOVERY FROM WOOD PROCESSING | FIRMENICH SA (CH) | 2023-11-16 | — | — | WO | claimed |
| US-20250290009-A1 | NEW LOW SULFUR TERPENE MIX RECOVERY FROM WOOD PROCESSING | FIRMENICH SA (CH) | 2025-09-18 | — | — | US | disclosed |
| EP-4522714-A1 | NEW LOW SULFUR TERPENE MIX RECOVERY FROM WOOD PROCESSING | Firmenich SA (CH) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023217712-A1 | NEW LOW SULFUR TERPENE MIX RECOVERY FROM WOOD PROCESSING | FIRMENICH SA (CH) | 2023-11-16 | — | — | WO | disclosed |
| CN-116924891-A | Method for preparing 2, 6-dimethoxy-4-propylphenol by catalyzing lignin to hydrogenolysis through cerium-zirconium composite metal oxide supported nickel | 华南理工大学 | 2023-10-24 | — | — | CN | disclosed |
| CN-115888802-A | Bimetal supported catalyst, preparation method and application thereof, and method for catalyzing depolymerization of lignin | 喀什大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-110312698-A | Between producing high-purity, bis- (4- alkylphenol) derivatives of m- coupling and application thereof | 鲁汶天主教大学 | 2019-10-08 | — | — | CN | disclosed |
| US-10221114-B2 | Liquid crystal compound having tetrafluoro cyclohexadiene structure showing negative anisotropy, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2019-03-05 | — | — | US | disclosed |
| US-20160200980-A1 | LIQUID CRYSTAL COMPOUND HAVING TETRAFLUORO CYCLOHEXADIENE STRUCTURE SHOWING NEGATIVE ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-07-14 | — | — | US | disclosed |
| WO-2012090369-A1 | PYROLYSIS METHOD FOR PLANT BIOMASS | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200980-A1 | LIQUID CRYSTAL COMPOUND HAVING TETRAFLUORO CYCLOHEXADIENE STRUCTURE SHOWING NEGATIVE ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | OCIAD2, CNOT1, OCIAD1 | HMGCR 4396/4885PRKCI 3936/4885ALOX5 708/4885 |
| US-10221114-B2 | Liquid crystal compound having tetrafluoro cyclohexadiene structure showing negative anisotropy, liquid crystal composition, and liquid crystal display device | OCIAD2, CNOT1, OCIAD1 | HMGCR 4396/4885PRKCI 3936/4885ALOX5 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.